ProCE Banner Activity

B 型肝炎の状況における HCC:アジア太平洋地域での考慮点

Text Module

世界のHBV 罹患者の 75% 超が在住する、アジア太平洋地域における HBV-関連の HCC の予防と治療について Grace LH Wong, MDから学ぶ

Released: June 22, 2021

Expiration: June 21, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Gilead Sciences, Inc.

Target Audience

このプログラムは、B 型肝炎の状況で、HCC を有する、またはそのリスクのある患者に治療を提供している医師、薬剤師、その他の医療従事者を対象としています。

Learning Objectives

Upon completion of this activity, participants should be able to:

  • HCC 発症のリスクが高い HBV 感染者の識別
  • アジア太平洋地域における適切な HBV 感染者のなかで、APASL ガイドライン–ベースの HCC スクリーニング戦略の適用
  • アジア太平洋地域における、B 型肝炎の状況で、HCC の診断と管理の諸分野全体にわたる戦略の開発

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD には報告すべき関連性のある利益相反はありません。

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD には報告すべき関連性のある利益相反はありません。

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA には報告すべき関連性のある利益相反はありません。

Jennifer Swanson, MEd

Associate Managing Editor, Hematology/Oncology
Clinical Care Options, LLC

Jennifer Swanson, PharmD には報告すべき関連性のある利益相反はありません。

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Goal


この活動の目標は、B 型肝炎患者における HCC リスクについて、臨床医の理解を向上させ、HCC スクリーニング、診断、オンコロジストとの共同管理の能力を向上させることです。